Idiopathic interstitial pneumonia natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 17: Line 17:




Rapidly deteriorating lung function and higher mortality have been associated with high serum level of epithelial or macrophage-related proteins such as SP-A, SP-D, KL-6 (Krebs von den Lungen-6), CCL18 (chemokine ligand-18), and MMP-7 (matrix metalloproteinase-7)  <ref name="Satoh-2006">{{Cite journal | last1 = Satoh | first1 = H. | last2 = Kurishima | first2 = K. | last3 = Ishikawa |first3 = H. | last4 = Ohtsuka | first4 = M. | title = Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. |journal = J Intern Med | volume = 260 | issue = 5 | pages = 429-34 | month = Nov | year = 2006 | doi = 10.1111/j.1365-2796.2006.01704.x | PMID = 17040248 }}</ref> <ref name="Prasse-2009">{{Cite journal | last1 = Prasse | first1 = A. | last2 = Probst | first2 = C. | last3 = Bargagli | first3 = E.| last4 = Zissel | first4 = G. | last5 = Toews | first5 = GB. | last6 = Flaherty | first6 = KR. | last7 = Olschewski | first7 = M. | last8 = Rottoli |first8 = P. | last9 = Müller-Quernheim | first9 = J. | title = Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. | journal = Am J Respir Crit Care Med | volume = 179 | issue = 8 | pages = 717-23 | month = Apr | year = 2009 | doi = 10.1164/rccm.200808-1201OC | PMID = 19179488 }}</ref> <ref name="Ishii-2003">{{Cite journal | last1 = Ishii | first1 = H. | last2 = Mukae | first2 = H. | last3 = Kadota | first3 = J. | last4 = Kaida | first4 = H. | last5 = Nagata | first5 = T. | last6 = Abe | first6 = K. | last7 = Matsukura | first7 = S. | last8 = Kohno | first8 = S. | title = High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. | journal = Thorax | volume = 58 | issue = 1 | pages = 52-7 | month = Jan | year = 2003 | doi = | PMID = 12511721 }}</ref>
For example some studies showed that rapidly deteriorating lung function and higher mortality have been associated with high serum level of epithelial or macrophage-related proteins such as SP-A, SP-D, KL-6 (Krebs von den Lungen-6), CCL18 (chemokine ligand-18), and MMP-7 (matrix metalloproteinase-7)  <ref name="Satoh-2006">{{Cite journal | last1 = Satoh | first1 = H. | last2 = Kurishima | first2 = K. | last3 = Ishikawa |first3 = H. | last4 = Ohtsuka | first4 = M. | title = Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. |journal = J Intern Med | volume = 260 | issue = 5 | pages = 429-34 | month = Nov | year = 2006 | doi = 10.1111/j.1365-2796.2006.01704.x | PMID = 17040248 }}</ref> <ref name="Prasse-2009">{{Cite journal | last1 = Prasse | first1 = A. | last2 = Probst | first2 = C. | last3 = Bargagli | first3 = E.| last4 = Zissel | first4 = G. | last5 = Toews | first5 = GB. | last6 = Flaherty | first6 = KR. | last7 = Olschewski | first7 = M. | last8 = Rottoli |first8 = P. | last9 = Müller-Quernheim | first9 = J. | title = Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. | journal = Am J Respir Crit Care Med | volume = 179 | issue = 8 | pages = 717-23 | month = Apr | year = 2009 | doi = 10.1164/rccm.200808-1201OC | PMID = 19179488 }}</ref> <ref name="Ishii-2003">{{Cite journal | last1 = Ishii | first1 = H. | last2 = Mukae | first2 = H. | last3 = Kadota | first3 = J. | last4 = Kaida | first4 = H. | last5 = Nagata | first5 = T. | last6 = Abe | first6 = K. | last7 = Matsukura | first7 = S. | last8 = Kohno | first8 = S. | title = High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. | journal = Thorax | volume = 58 | issue = 1 | pages = 52-7 | month = Jan | year = 2003 | doi = | PMID = 12511721 }}</ref>


==References==
==References==

Revision as of 17:26, 15 November 2013

Idiopathic Interstitial Pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Idiopathic interstitial pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

Endoscopy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Idiopathic interstitial pneumonia natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Idiopathic interstitial pneumonia natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onIdiopathic interstitial pneumonia natural history, complications and prognosis

CDC on Idiopathic interstitial pneumonia natural history, complications and prognosis

Idiopathic interstitial pneumonia natural history, complications and prognosisin the news

on Idiopathic interstitial pneumonia natural history, complications and prognosis

Directions to Hospitals Treating Idiopathic interstitial pneumonia

Risk calculators and risk factors for Idiopathic interstitial pneumonia natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]


Natural history and Complications

Biomarkers

The functional lung capacity, pulmonary functions and mortality have been linked to some biomarkers. This Table summarizes the findings of different research studies.

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15].


For example some studies showed that rapidly deteriorating lung function and higher mortality have been associated with high serum level of epithelial or macrophage-related proteins such as SP-A, SP-D, KL-6 (Krebs von den Lungen-6), CCL18 (chemokine ligand-18), and MMP-7 (matrix metalloproteinase-7) [4] [16] [17]

References

  1. ↑ Takahashi, H.; Fujishima, T.; Koba, H.; Murakami, S.; Kurokawa, K.; Shibuya, Y.; Shiratori, M.; Kuroki, Y.; Abe, S. (2000). "Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent". Am J Respir Crit Care Med. 162 (3 Pt 1): 1109–14. doi:10.1164/ajrccm.162.3.9910080. PMID 10988138. Unknown parameter |month= ignored (help)
  2. ↑ Greene, KE.; King, TE.; Kuroki, Y.; Bucher-Bartelson, B.; Hunninghake, GW.; Newman, LS.; Nagae, H.; Mason, RJ. (2002). "Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis". Eur Respir J. 19 (3): 439–46. PMID 11936520. Unknown parameter |month= ignored (help)
  3. ↑ Yokoyama, A.; Kondo, K.; Nakajima, M.; Matsushima, T.; Takahashi, T.; Nishimura, M.; Bando, M.; Sugiyama, Y.; Totani, Y. (2006). "Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis". Respirology. 11 (2): 164–8. doi:10.1111/j.1440-1843.2006.00834.x. PMID 16548901. Unknown parameter |month= ignored (help)
  4. ↑ 4.0 4.1 Satoh, H.; Kurishima, K.; Ishikawa, H.; Ohtsuka, M. (2006). "Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases". J Intern Med. 260 (5): 429–34. doi:10.1111/j.1365-2796.2006.01704.x. PMID 17040248. Unknown parameter |month= ignored (help)
  5. ↑ Takahashi, H.; Shiratori, M.; Kanai, A.; Chiba, H.; Kuroki, Y.; Abe, S. (2006). "Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D.". Respirology. 11 Suppl: S51–4. doi:10.1111/j.1440-1843.2006.00809.x. PMID 16423272. Unknown parameter |month= ignored (help)
  6. ↑ Daniil, ZD.; Papageorgiou, E.; Koutsokera, A.; Kostikas, K.; Kiropoulos, T.; Papaioannou, AI.; Gourgoulianis, KI. (2008). "Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis". Pulm Pharmacol Ther. 21 (1): 26–31. doi:10.1016/j.pupt.2006.10.005. PMID 17161968.
  7. ↑ Rosas, IO.; Richards, TJ.; Konishi, K.; Zhang, Y.; Gibson, K.; Lokshin, AE.; Lindell, KO.; Cisneros, J.; Macdonald, SD. (2008). "MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis". PLoS Med. 5 (4): e93. doi:10.1371/journal.pmed.0050093. PMID 18447576. Unknown parameter |month= ignored (help)
  8. ↑ Kinder, BW.; Brown, KK.; McCormack, FX.; Ix, JH.; Kervitsky, A.; Schwarz, MI.; King, TE. (2009). "Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis". Chest. 135 (6): 1557–63. doi:10.1378/chest.08-2209. PMID 19255294. Unknown parameter |month= ignored (help)
  9. ↑ Barlo, NP.; van Moorsel, CH.; Ruven, HJ.; Zanen, P.; van den Bosch, JM.; Grutters, JC. (2009). "Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis". Sarcoidosis Vasc Diffuse Lung Dis. 26 (2): 155–61. PMID 20560296. Unknown parameter |month= ignored (help)
  10. ↑ Prasse, A.; Pechkovsky, DV.; Toews, GB.; Schäfer, M.; Eggeling, S.; Ludwig, C.; Germann, M.; Kollert, F.; Zissel, G. (2007). "CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis". Arthritis Rheum. 56 (5): 1685–93. doi:10.1002/art.22559. PMID 17469163. Unknown parameter |month= ignored (help)
  11. ↑ Gilani, SR.; Vuga, LJ.; Lindell, KO.; Gibson, KF.; Xue, J.; Kaminski, N.; Valentine, VG.; Lindsay, EK.; George, MP. (2010). "CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis". PLoS One. 5 (1): e8959. doi:10.1371/journal.pone.0008959. PMID 20126467.
  12. ↑ Richards, TJ.; Kaminski, N.; Baribaud, F.; Flavin, S.; Brodmerkel, C.; Horowitz, D.; Li, K.; Choi, J.; Vuga, LJ. (2012). "Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis". Am J Respir Crit Care Med. 185 (1): 67–76. doi:10.1164/rccm.201101-0058OC. PMID 22016448. Unknown parameter |month= ignored (help)
  13. ↑ McKeown, S.; Richter, AG.; O'Kane, C.; McAuley, DF.; Thickett, DR. (2009). "MMP expression and abnormal lung permeability are important determinants of outcome in IPF". Eur Respir J. 33 (1): 77–84. doi:10.1183/09031936.00060708. PMID 18829682. Unknown parameter |month= ignored (help)
  14. ↑ Shinoda, H.; Tasaka, S.; Fujishima, S.; Yamasawa, W.; Miyamoto, K.; Nakano, Y.; Kamata, H.; Hasegawa, N.; Ishizaka, A. (2009). "Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis". Respiration. 78 (3): 285–92. doi:10.1159/000207617. PMID 19270434.
  15. ↑ Richter, AG.; McKeown, S.; Rathinam, S.; Harper, L.; Rajesh, P.; McAuley, DF.; Heljasvaara, R.; Thickett, DR. (2009). "Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis". Thorax. 64 (2): 156–61. doi:10.1136/thx.2008.102814. PMID 18852160. Unknown parameter |month= ignored (help)
  16. ↑ Prasse, A.; Probst, C.; Bargagli, E.; Zissel, G.; Toews, GB.; Flaherty, KR.; Olschewski, M.; Rottoli, P.; Müller-Quernheim, J. (2009). "Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis". Am J Respir Crit Care Med. 179 (8): 717–23. doi:10.1164/rccm.200808-1201OC. PMID 19179488. Unknown parameter |month= ignored (help)
  17. ↑ Ishii, H.; Mukae, H.; Kadota, J.; Kaida, H.; Nagata, T.; Abe, K.; Matsukura, S.; Kohno, S. (2003). "High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia". Thorax. 58 (1): 52–7. PMID 12511721. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Idiopathic_interstitial_pneumonia_natural_history,_complications_and_prognosis&oldid=913105"